87 completed, 20 unknown, 10 withdrawn, 8 terminated. 45 Phase 2, 38 Phase 3, 38 Phase 4, 15 Phase 1, 10 Not applicable.
Follow Eylea: new trials by email Literature Review of Eylea trials Research Report on Eylea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VGFTe-(HD)-OD-2566: Adjunctive Aflibercept Ahmed Glaucoma Valve (AAA) Study Aflibercept Injection, Ahmed Tube Surgery - Glaucoma | Phase 2 | Not yet recruiting | University of Miami | 100 | 2026-12-01 | 2026-10-23 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 1104 | 2026-09-25 | 2026-10-23 |
| A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004) MK-8748, Aflibercept - Diabetic Retinopathy, Macular Edema | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 960 | 2026-08-27 | 2026-10-23 |
| A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO Tabirafusp tedromer, Aflibercept (2.0 mg) - Diabetic Macular Edema (DME) | Phase 3 | Recruiting | Kodiak Sciences Inc | 910 | 2026-08-03 | 2026-08-21 |
| A Study to Compare GNR-139 and Eylea® in Patients With nAMD aflibercept, Eylea - nAMD | Phase 3 | Recruiting | AO GENERIUM | 180 | 2026-07-22 | 2026-09-30 |
| Impact of Intravitreal Faricimab on Renal Function in Diabetic Patients Intravitreal injection of Faricimab or Aflibercept 2 mg - Renal Function Disorder, Diabetic Macular Edema (DME) | Not applicable | Recruiting | University Hospital, Alexandroupolis | 60 | 2025-03-10 | 2025-04-24 |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma ZIV-Aflibercept, Cemiplimab - Metastatic Uveal Melanoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 32 | 2024-11-04 | 2025-12-04 |
| A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK Tarcocimab tedromer, Tabirafusp tedromer, Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Active not recruiting | Kodiak Sciences Inc | 675 | 2024-08-23 | 2026-04-29 |
| Study of EYP-1901 in Patients With Diabetic Macular Edema (DME) EYP-1901, Aflibercept 2Mg/0.05Ml Inj,Oph - Diabetic Macular Edema | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 27 | 2024-01-15 | 2025-03-04 |
| 4D-150 in Patients With Diabetic Macular Edema 4D-150 IVT, Aflibercept IVT - Diabetic Macular Edema, Diabetic Retinopathy | Phase 2 | Active not recruiting | 4D Molecular Therapeutics | 72 | 2023-08-09 | 2026-08-21 |
| Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration CLS-AX, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Clearside Biomedical, Inc. | 60 | 2023-05-31 | 2025-07-25 |
| Efficacy and Safety of RC28-E Versus Aflibercept RC28-E, Aflibercept - Wet Age-related Macular Degeneration | Phase 3 | Unknown | RemeGen Co., Ltd. | 432 | 2023-03-14 | 2023-08-31 |
| Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With Immediate T&E Brolucizumab, Aflibercept - Age-Related Macular Degeneration | Phase 4 | Completed | The University of Hong Kong | 30 | 2022-07-25 | 2024-05-08 |
| Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) EYP-1901, Aflibercept 2mg/0.05mL Inj,Oph - Wet Age-related Macular Degeneration | Phase 2 | Completed | EyePoint Pharmaceuticals, Inc. | 161 | 2022-06-30 | 2025-10-15 |
| Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With and Without Diabetic Retinopathy Standard of Care, Aflibercept - Diabetic Retinopathy, DR | Phase 2 | Enrolling by invitation | AbbVie | 100 | 2022-04-04 | 2026-08-05 |
| Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration SCB-420, Aflibercept - Wet Age-related Macular Degeneration | Phase 1 | Withdrawn | Clover Biopharmaceuticals AUS Pty | 2022-04-01 | 2022-04-19 | |
| Vascular Endothelial Growth Factor (VEGF) Levels in Retinal Vein Occlusion (RVO) During Anti-VEGF Treatment Aflibercept Ophthalmic - Retinal Vein Occlusion | Phase 4 | Terminated | Wake Forest University Health Sciences | 17 | 2021-10-06 | 2025-02-24 |
| Study Evaluating the Treatment of OTX-TKI for Subjects With Neovascular Age-related Macular Degeneration OTX-TKI/Sham, Aflibercept/Sham - Neovascular Age-Related Macular Degeneration | Phase 1 | Completed | Ocular Therapeutix, Inc. | 21 | 2021-07-28 | 2024-01-26 |
| Study to Compare Efficacy and Safety of CT-P42 in Comparison With Eylea in Patients With Diabetic Macular Edema CT-P42, Eylea - Diabetic Macular Edema (DME) | Phase 3 | Completed | Celltrion | 348 | 2021-07-22 | 2023-12-05 |
| A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) KSI-301, Aflibercept, Sham Procedure - Wet Age-related Macular Degeneration | Phase 3 | Completed | Kodiak Sciences Inc | 557 | 2021-06-23 | 2024-07-03 |
Showing 20 of 138. Sign in to see all of them.
Macular Degeneration (27) · Macular Edema (20) · Diabetic Retinopathy (18) · Retinal Vein Occlusion (13) · Wet Macular Degeneration (11) · Retinal Diseases (10) · Vision Disorders (9) · Eye Diseases (8) · Retinal Degeneration (8) · Diabetes Mellitus (6) · Polypoidal Choroidal Vasculopathy (6) · Vision, Low (5) · Choroidal Neovascularization (3) · Vitreous Hemorrhage (3) · Blindness (2)
Novartis Pharmaceuticals (12) · Kodiak Sciences Inc (7) · Hoffmann-La Roche (6) · Jaeb Center for Health Research (4) · National Cancer Institute (NCI) (4) · Clearside Biomedical, Inc. (3) · Unity Health Toronto (3) · Arshad Khanani (2) · EyePoint Pharmaceuticals, Inc. (2) · Greater Houston Retina Research (2) · Hadassah Medical Organization (2) · Merck Sharp & Dohme LLC (2) · Moorfields Eye Hospital NHS Foundation Trust (2) · Northern California Retina Vitreous Associates (2) · Ophthotech Corporation (2)
United States (84) · Germany (15) · Canada (14) · Hungary (12) · Israel (12) · Spain (12) · Italy (11) · Poland (11) · Puerto Rico (11) · South Korea (11) · Australia (10) · Czechia (10) · France (10) · United Kingdom (10) · Russia (9)
Pablo Velazquez-Martin, MD (6) · Dennis M Marcus, MD (2) · Rajeev Muni, MD (2) · Thomas Ciulla, MD (2) · Adam Glassman, MS (1) · Adam Rothman, MD (1) · Ahmad Tarhini (1) · Ahmad Tarhini, MD, PHD (1) · Allen Ho, MD (1) · Amy C Schefler, MD (1) · Anders Kvanta, MD PhD (1) · Andrew Antoszyk, MD (1)
PMID 35085502, PMID 35085503, PMID 36246184, PMID 36246941, PMID 36897413, PMID 37294433, PMID 37585454, PMID 38158159, PMID 38280653, PMID 38382813, PMID 38758639, PMID 38852921, PMID 40668667, PMID 41534798, PMID 41712218, PMID 42753135, PMID 42771326, PMID 12750101, PMID 16483659, PMID 16523231, PMID 16581423, PMID 16787141, PMID 16935211, PMID 19549103, PMID 19936307, PMID 20136420, PMID 25001321, PMID 25595177, PMID 26114826, PMID 27020759, PMID 27124775, PMID 27409478, PMID 27465105, PMID 27597740, PMID 28492910, PMID 28814412, PMID 30676617, PMID 30681643, PMID 30957581, PMID 31016030, PMID 31037289, PMID 31169862, PMID 31367468, PMID 31564356, PMID 31600368, PMID 31757691, PMID 31917731, PMID 32041720, PMID 32374423, PMID 32557168
2017 (4), 2018 (3), 2019 (2), P30CA016672 (2), 2014 (1), 2015 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM62209 (1), P30CA033572 (1), U01CA062461 (1), U01CA062490 (1), U10EY023521 (1)